By IANS,
New Delhi : The US government has filed a complaint against India’s largest pharmaceutical company Ranbaxy Laboratories and its US-based consultant Parexel Consulting, for forgery and concealing data.
Th US government filed a motion in a Maryland court for procuring relevant documents to investigate a case against Ranbaxy. It alleges the pharma giant had tried to forge and conceal data in order to get a favourable judgement in an ongoing investigation into the sale of sub-standard drugs in that country.
A Ranbaxy spokesperson told IANS that a motion has been filed seeking documents and no legal proceedings for prosecution had been started. “We deny the allegations contained in the motion, but will cooperate with the inquiry,” he said.
He said the allegations of systematic fraudulent conduct about drugs manufactured in the company’s plant in India were baseless.
He said Ranbaxy would file its response to the court on Monday.
If proved, the allegations could have a serious impact on Ranbaxy’s US operations that contribute over 20 percent to the company’s total turnover, which is over Rs.60 billion ($1.4 billion).
“The United States Food and Drugs Administration has verified over 200 random samples of various products marketed by the company in the US and all were found to be complying with all the specifications as per the filing,” said the spokesperson.